203 related articles for article (PubMed ID: 26837773)
1. Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer.
Gui SL; Teng LC; Wang SQ; Liu S; Lin YL; Zhao XL; Liu L; Sui HY; Yang Y; Liang LC; Wang ML; Li XY; Cao Y; Li FY; Wang WQ
Int Urol Nephrol; 2016 May; 48(5):701-9. PubMed ID: 26837773
[TBL] [Abstract][Full Text] [Related]
2. Chemokine CXCL3 mediates prostate cancer cells proliferation, migration and gene expression changes in an autocrine/paracrine fashion.
Xin H; Cao Y; Shao ML; Zhang W; Zhang CB; Wang JT; Liang LC; Shao WW; Qi YL; Li Y; Zhang ZY; Yang Z; Sun YH; Zhang PX; Jia LL; Wang WQ
Int Urol Nephrol; 2018 May; 50(5):861-868. PubMed ID: 29524043
[TBL] [Abstract][Full Text] [Related]
3. CXCL3 overexpression promotes the tumorigenic potential of uterine cervical cancer cells via the MAPK/ERK pathway.
Qi YL; Li Y; Man XX; Sui HY; Zhao XL; Zhang PX; Qu XS; Zhang H; Wang BX; Li J; Qi SF; Jia LL; Luan HY; Zhang CB; Wang WQ
J Cell Physiol; 2020 May; 235(5):4756-4765. PubMed ID: 31667838
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of CXCL3 in colon cancer promotes malignant behaviors of tumor cells in an ERK-dependent manner.
Cheng Y; Yang X; Liang L; Xin H; Dong X; Li W; Li J; Guo X; Li Y; He J; Zhang C; Wang W
BMC Cancer; 2023 Nov; 23(1):1162. PubMed ID: 38031087
[TBL] [Abstract][Full Text] [Related]
5. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.
Lu Y; Wang J; Xu Y; Koch AE; Cai Z; Chen X; Galson DL; Taichman RS; Zhang J
Mol Cancer Res; 2008 Apr; 6(4):546-54. PubMed ID: 18344492
[TBL] [Abstract][Full Text] [Related]
6. NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth.
Wang W; Li Y; Li Y; Hong A; Wang J; Lin B; Li R
Int J Cancer; 2009 Feb; 124(3):521-30. PubMed ID: 18975380
[TBL] [Abstract][Full Text] [Related]
7. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis.
Mochizuki H; Matsubara A; Teishima J; Mutaguchi K; Yasumoto H; Dahiya R; Usui T; Kamiya K
Biochem Biophys Res Commun; 2004 Jul; 320(3):656-63. PubMed ID: 15240098
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.
Maxwell PJ; Neisen J; Messenger J; Waugh DJ
Oncotarget; 2014 Jul; 5(13):4895-908. PubMed ID: 24970800
[TBL] [Abstract][Full Text] [Related]
9. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix.
Engl T; Relja B; Blumenberg C; Müller I; Ringel EM; Beecken WD; Jonas D; Blaheta RA
Life Sci; 2006 Mar; 78(16):1784-93. PubMed ID: 16263140
[TBL] [Abstract][Full Text] [Related]
10. Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation.
Tsai CY; Lee TS; Kou YR; Wu YL
J Cell Biochem; 2009 Oct; 108(2):489-98. PubMed ID: 19626664
[TBL] [Abstract][Full Text] [Related]
11. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.
Jin Y; Cui Z; Li X; Jin X; Peng J
Oncotarget; 2017 Apr; 8(16):26090-26099. PubMed ID: 28212533
[TBL] [Abstract][Full Text] [Related]
13. CCR2 expression correlates with prostate cancer progression.
Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
[TBL] [Abstract][Full Text] [Related]
14. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
Arya M; Patel HR; McGurk C; Tatoud R; Klocker H; Masters J; Williamson M
J Exp Ther Oncol; 2004 Dec; 4(4):291-303. PubMed ID: 15844659
[TBL] [Abstract][Full Text] [Related]
15. Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection.
Gregg JL; Brown KE; Mintz EM; Piontkivska H; Fraizer GC
BMC Cancer; 2010 Apr; 10():165. PubMed ID: 20426842
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Blockade of Spinal CXCL3/CXCR2 Signaling by NVP CXCR2 20, a Selective CXCR2 Antagonist, Reduces Neuropathic Pain Following Peripheral Nerve Injury.
Piotrowska A; Rojewska E; Pawlik K; Kreiner G; Ciechanowska A; Makuch W; Nalepa I; Mika J
Front Immunol; 2019; 10():2198. PubMed ID: 31616413
[TBL] [Abstract][Full Text] [Related]
17. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
Liao W; Overman MJ; Boutin AT; Shang X; Zhao D; Dey P; Li J; Wang G; Lan Z; Li J; Tang M; Jiang S; Ma X; Chen P; Katkhuda R; Korphaisarn K; Chakravarti D; Chang A; Spring DJ; Chang Q; Zhang J; Maru DM; Maeda DY; Zebala JA; Kopetz S; Wang YA; DePinho RA
Cancer Cell; 2019 Apr; 35(4):559-572.e7. PubMed ID: 30905761
[TBL] [Abstract][Full Text] [Related]
18. TGF-β Effects on Prostate Cancer Cell Migration and Invasion Require FosB.
Barrett CS; Millena AC; Khan SA
Prostate; 2017 Jan; 77(1):72-81. PubMed ID: 27604827
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cells regulate the proliferation of T cells via the growth-related oncogene/CXC chemokine receptor, CXCR2.
Lee YS; Won KJ; Park SW; Lee HW; Kim B; Kim JH; Kim DK
Cell Immunol; 2012 Sep; 279(1):1-11. PubMed ID: 23023221
[TBL] [Abstract][Full Text] [Related]
20. The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.
Yamamoto Y; Kuroda K; Sera T; Sugimoto A; Kushiyama S; Nishimura S; Togano S; Okuno T; Yoshii M; Tamura T; Toyokawa T; Tanaka H; Muguruma K; Ohira M; Yashiro M
Anticancer Res; 2019 Dec; 39(12):6645-6652. PubMed ID: 31810929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
